194 related articles for article (PubMed ID: 21222631)
1. Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease.
Palacios HH; Yendluri BB; Parvathaneni K; Shadlinski VB; Obrenovich ME; Leszek J; Gokhman D; Gąsiorowski K; Bragin V; Aliev G
CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):149-62. PubMed ID: 21222631
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases.
Aliev G; Li Y; Palacios HH; Obrenovich ME
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):222-41. PubMed ID: 21906026
[TBL] [Abstract][Full Text] [Related]
3. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice.
Aliev G; Seyidova D; Lamb BT; Obrenovich ME; Siedlak SL; Vinters HV; Friedland RP; LaManna JC; Smith MA; Perry G
Neurol Res; 2003 Sep; 25(6):665-74. PubMed ID: 14503022
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease.
Verri M; Pastoris O; Dossena M; Aquilani R; Guerriero F; Cuzzoni G; Venturini L; Ricevuti G; Bongiorno AI
Int J Immunopathol Pharmacol; 2012; 25(2):345-53. PubMed ID: 22697066
[TBL] [Abstract][Full Text] [Related]
5. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease.
Aliev G; Smith MA; Obrenovich ME; de la Torre JC; Perry G
Neurotox Res; 2003; 5(7):491-504. PubMed ID: 14715433
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease.
Aliev G; Priyadarshini M; Reddy VP; Grieg NH; Kaminsky Y; Cacabelos R; Ashraf GM; Jabir NR; Kamal MA; Nikolenko VN; Zamyatnin AA; Benberin VV; Bachurin SO
Curr Med Chem; 2014; 21(19):2208-17. PubMed ID: 24372221
[TBL] [Abstract][Full Text] [Related]
7. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease.
Aliev G; Palacios HH; Walrafen B; Lipsitt AE; Obrenovich ME; Morales L
Int J Biochem Cell Biol; 2009 Oct; 41(10):1989-2004. PubMed ID: 19703659
[TBL] [Abstract][Full Text] [Related]
8. An antioxidant specifically targeting mitochondria delays progression of Alzheimer's disease-like pathology.
Stefanova NA; Muraleva NA; Maksimova KY; Rudnitskaya EA; Kiseleva E; Telegina DV; Kolosova NG
Aging (Albany NY); 2016 Oct; 8(11):2713-2733. PubMed ID: 27750209
[TBL] [Abstract][Full Text] [Related]
9. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: a new approach to therapy.
Sochocka M; Koutsouraki ES; Gasiorowski K; Leszek J
CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):870-81. PubMed ID: 23469836
[TBL] [Abstract][Full Text] [Related]
10. Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress.
Quintanilla RA; Orellana JA; von Bernhardi R
Arch Med Res; 2012 Nov; 43(8):632-44. PubMed ID: 23142264
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease.
Aliyev A; Chen SG; Seyidova D; Smith MA; Perry G; de la Torre J; Aliev G
J Neurol Sci; 2005 Mar; 229-230():285-92. PubMed ID: 15760652
[TBL] [Abstract][Full Text] [Related]
12. The redox chemistry of the Alzheimer's disease amyloid beta peptide.
Smith DG; Cappai R; Barnham KJ
Biochim Biophys Acta; 2007 Aug; 1768(8):1976-90. PubMed ID: 17433250
[TBL] [Abstract][Full Text] [Related]
13. The immunopathogenic role of reactive oxygen species in Alzheimer disease.
Mohsenzadegan M; Mirshafiey A
Iran J Allergy Asthma Immunol; 2012 Sep; 11(3):203-16. PubMed ID: 22947905
[TBL] [Abstract][Full Text] [Related]
14. Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.
Lanzillotta C; Di Domenico F; Perluigi M; Butterfield DA
CNS Drugs; 2019 Oct; 33(10):957-969. PubMed ID: 31410665
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Dysfunction in Neocortex and Hippocampus of Olfactory Bulbectomized Mice, a Model of Alzheimer's Disease.
Avetisyan AV; Samokhin AN; Alexandrova IY; Zinovkin RA; Simonyan RA; Bobkova NV
Biochemistry (Mosc); 2016 Jun; 81(6):615-23. PubMed ID: 27301290
[TBL] [Abstract][Full Text] [Related]
16. Dietary zeolite supplementation reduces oxidative damage and plaque generation in the brain of an Alzheimer's disease mouse model.
Montinaro M; Uberti D; Maccarinelli G; Bonini SA; Ferrari-Toninelli G; Memo M
Life Sci; 2013 May; 92(17-19):903-10. PubMed ID: 23562853
[TBL] [Abstract][Full Text] [Related]
17. Small molecules as therapeutic drugs for Alzheimer's disease.
Oliver DMA; Reddy PH
Mol Cell Neurosci; 2019 Apr; 96():47-62. PubMed ID: 30877034
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress and Alzheimer disease.
Christen Y
Am J Clin Nutr; 2000 Feb; 71(2):621S-629S. PubMed ID: 10681270
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer's Disease.
Ajith TA; Padmajanair G
Curr Aging Sci; 2015; 8(3):235-40. PubMed ID: 25986626
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective strategies involving ROS in Alzheimer disease.
Dumont M; Beal MF
Free Radic Biol Med; 2011 Sep; 51(5):1014-26. PubMed ID: 21130159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
